Literature DB >> 17371259

The role of SHIP1 in T-lymphocyte life and death.

G Gloire1, C Erneux, J Piette.   

Abstract

SHIP1 [SH2 (Src homology 2)-containing inositol phosphatase-1], an inositol 5-phosphatase expressed in haemopoietic cells, acts by hydrolysing the 5-phosphates from PtdIns(3,4,5)P(3) and Ins(1,3,4,5)P(4), thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathway. SHIP1 plays a major role in inhibiting proliferation of myeloid cells. As a result, SHIP1(-/-) mice have an increased number of neutrophils and monocytes/macrophages due to enhanced survival and proliferation of their progenitors. Although SHIP1 contributes to PtdIns(3,4,5)P(3) metabolism in T-lymphocytes, its exact role in this cell type is much less explored. Jurkat cells have recently emerged as an interesting tool to study SHIP1 function in T-cells because they do not express SHIP1 at the protein level, thereby allowing reintroduction experiments in a relatively easy-to-use system. Data obtained from SHIP1 reintroduction have revealed that SHIP1 not only acts as a negative player in T-cell lines proliferation, but also regulates critical pathways, such as NF-kappaB (nuclear factor kappaB) activation, and also appears to remarkably inhibit T-cell apoptosis. On the other hand, experiments using primary T-cells from SHIP1(-/-) mice have highlighted a new role for SHIP1 in regulatory T-cell development, but also emphasize that this protein is not required for T-cell proliferation. In support of these results, SHIP1(-/-) mice are lymphopenic, suggesting that SHIP1 function in T-cells differs from its role in the myeloid lineage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371259     DOI: 10.1042/BST0350277

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  6 in total

1.  MiR-155-regulated molecular network orchestrates cell fate in the innate and adaptive immune response to Mycobacterium tuberculosis.

Authors:  Alissa C Rothchild; James R Sissons; Shahin Shafiani; Christopher Plaisier; Deborah Min; Dat Mai; Mark Gilchrist; Jacques Peschon; Ryan P Larson; Andreas Bergthaler; Nitin S Baliga; Kevin B Urdahl; Alan Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-28       Impact factor: 11.205

2.  Role of SHIP1 in Invariant NKT Cell Development and Functions.

Authors:  Courtney K Anderson; Alexander I Salter; Leon E Toussaint; Emma C Reilly; Céline Fugère; Neetu Srivastava; William G Kerr; Laurent Brossay
Journal:  J Immunol       Date:  2015-07-31       Impact factor: 5.422

Review 3.  Roles of the miR-155 in Neuroinflammation and Neurological Disorders: A Potent Biological and Therapeutic Target.

Authors:  Seyed Hamidreza Rastegar-Moghaddam; Alireza Ebrahimzadeh-Bideskan; Sara Shahba; Amir Mohammad Malvandi; Abbas Mohammadipour
Journal:  Cell Mol Neurobiol       Date:  2022-02-02       Impact factor: 5.046

4.  Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function.

Authors:  Shari Pilon-Thomas; Nadine Nelson; Nasreen Vohra; Maya Jerald; Laura Pendleton; Karoly Szekeres; Tomar Ghansah
Journal:  PLoS One       Date:  2011-11-22       Impact factor: 3.240

5.  THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Authors:  Ikuya Miki; Tsutomu Nakamura; Akiko Kuwahara; Motohiro Yamamori; Kohshi Nishiguchi; Takao Tamura; Tatsuya Okuno; Hideaki Omatsu; Shigeto Mizuno; Midori Hirai; Takeshi Azuma; Toshiyuki Sakaeda
Journal:  Int J Med Sci       Date:  2012-10-23       Impact factor: 3.738

Review 6.  Regulatory T Cells: Molecular Actions on Effector Cells in Immune Regulation.

Authors:  Asiel Arce-Sillas; Diana Denisse Álvarez-Luquín; Beatriz Tamaya-Domínguez; Sandra Gomez-Fuentes; Abel Trejo-García; Marlene Melo-Salas; Graciela Cárdenas; Juan Rodríguez-Ramírez; Laura Adalid-Peralta
Journal:  J Immunol Res       Date:  2016-05-19       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.